Abstract

The single use of the programmed cell death protein 1 inhibitor camrelizumab has been studied a lot. However, the comparison of its combined use in various types of advanced lung cancer and whether it has a better application effect has been studied in this experiment and speculate on the immune mechanism after its use. From September 2019 to April 2023 (18 mo including follow-up time), 100 patients with advanced lung cancer treated with camrelizumab were selected and divided into 2 groups according to patient’s interest. 50 patients were divided into camrelizumab (200 mg)+platinum-based chemotherapy as the control group. The 50 patients in the experimental group received camrelizumab (200 mg) and apatinib (250 mg, once/d)+platinum-based chemotherapy. After 2 cycles of treatment, we compared the clinical efficacy of the two groups, observed the adverse drug reactions of the two groups, follow up for 12 mo and observed the progression-free survival time and median survival time of the two groups. In the experimental group the objective response rate=30 % and disease control rate=90 %, and the objective response rate=14 % and disease control rate=40 % in the control group, which means the curative effect of the experimental group was much better than that of the control group (p<0.05). Both groups had some adverse reactions, but they were all in grade 1 or 2 and there was no serious life-threatening (p>0.05). The overall survival time of the control group was 8.44±1.70 mo and the experimental group was 15.78±1.98 mo (p<0.05). The overall survival time of experimental group was slightly longer than that of the control group. Camrelizumab with platinum-based chemotherapy in the control group has a certain application effect. However, camrelizumab with apatinib and platinum-based chemotherapy in the experimental group had better curative effect for patients.